# The HIV Prevention Pipeline

### In development: Preclinical and clinical



Long-acting implants



Preventive vaccines



Multipurpose vaginal ring



Long-acting vaginal ring



**Patches** 



Douche



Vaginal/

Mucosal

Inserts

Vaginal Film



Vaginal Gel Monthly oral PrEP



**Broadly** neutralizing antibodies



Injectable

## In development: Efficacy trials under way



Daily oral PrEP



Combo oral PrEP/OC

Possible dual pill to market by 2025

### **Newly Approved and** Recommended



Dapivirine vaginal ring



Injectable cabotegravir



Iniectable lenacapavir

And in implementation science projects:

www.prepwatch.org/resources/ implementation-study-tracker/

## **Currently available**



**HIV** treatment for people living with HIV/U=U



Male & female condoms



Voluntary medical male circumcision



Syringe exchange programs



Daily oral PrEP



Event-driven for some populations

<sup>1</sup> In Oct 2019, US FDA approved F/TAF for adults and adolescents who have no HIV risk from receptive vaginal sex; still in development for cisgender women.

<sup>&</sup>lt;sup>2</sup> Efficacy trials not required; bioequivalency of the two approved products when dosed together may be all that is required.